NASDAQ: RKDAArcadia Biosciences Inc Stock
$0.69+0.01 (+1.47%)
Updated Jun 26, 2026
RKDA Price
$0.69
Fair Value Price
N/A
Market Cap
$1.42M
52 Week Low
$0.65
52 Week High
$6.71
P/E
-0.12x
P/B
0.49x
P/S
0.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.76M
Earnings
-$9.32M
Gross Margin
34.5%
Operating Margin
-195.78%
Profit Margin
-195.9%
Debt to Equity
0.85
Operating Cash Flow
-$4M
Beta
0.85
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
RKDA Overview
Arcadia Biosciences, Inc. is a U.S.-based company that provides plant-derived health and well-being products. Additionally, it is actively engaged in agricultural research and development, with a particular focus on improving wheat crops. The aim of these innovations is to enhance farmers' economic stability by boosting crop performance in the field, increasing their value for food and wellness applications, and expanding their potential for industrial uses. Established in 2002, the company's main office is located in Davis, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RKDA's potential to beat the market
- RKDA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Food
Industry Rating
C
RKDA
RankedUnranked of 45
RankedUnranked of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $170.38 | A | |
| $21.02 | A | |
| $12.54 | A |
Be the first to know about important RKDA news, forecast changes, insider trades & much more!
RKDA News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RKDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RKDA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RKDA is good value based on its book value relative to its share price (0.49x), compared to the US Packaged Foods industry average (1.47x)
P/B vs Industry Valuation
RKDA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RKDA due diligence checks available for Premium users.
Valuation
RKDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
-0.11x
Market
12.38x
RKDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.49x
Industry
1.47x
RKDA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RKDA's financial health
Profit margin
Revenue
$1.1M
Net Income
-$4.4M
Profit Margin
-398.6%
RKDA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RKDA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.3M
Liabilities
$2.4M
Debt to equity
0.85
RKDA's short-term assets ($5.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RKDA's short-term assets ($5.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RKDA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RKDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
$0.0
Financing
$1.8M
RKDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RKDA vs Food Stocks
Arcadia Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.